Clinicopathologic characteristics and outcomes of lupus nephritis with positive antineutrophil cytoplasmic antibody

References

• Li C, Zhou ML, Liang DD, et al. Treatment and clinicopathological characteristics of lupus nephritis with anti-neutrophil cytoplasmic antibody positivity: a case-control study. BMJ Open. 2017;7:e015668.
   PubMed Web of Science ®Google Scholar
• Galeazzi M, Morozzi G, Sebastiani GD, et al. Anti-neutrophil cytoplasmic antibodies in 566 European patients with systemic lupus erythematosus: prevalence, clinical associations and correlation with other autoantibodies. European Concerted Action on the Immunogenetics of SLE. Clin Exp Rheumatol. 1998;16:541–546.
   PubMed Web of Science ®Google Scholar
• Nishiya K, Chikazawa H, Nishimura S, et al. Anti-neutrophil cytoplasmic antibody in patients with systemic lupus erythematosus is unrelated to clinical features. Clin Rheumatol. 1997;16:70–75.
   PubMed Web of Science ®Google Scholar
• Pan HF, Fang XH, Wu GC, et al. Anti-neutrophil cytoplasmic antibodies in new-onset systemic lupus erythematosus and lupus nephritis. Inflammation. 2008;31:260–265.
   PubMed Web of Science ®Google Scholar
• Chin HJ, Ahn C, Lim CS, et al. Clinical implications of antineutrophil cytoplasmic antibody test in lupus nephritis. Am J Nephrol. 2000;20:57–63.
   PubMed Web of Science ®Google Scholar
• Sethi S, Fervenza FC. Standardized classification and reporting of glomerulonephritis. Nephrol Dial Transplant. 2019;34:193–199.
   PubMed Web of Science ®Google Scholar
• Olson SW, Lee JJ, Poirier M, et al. Anti-myeloperoxidase antibodies associate with future proliferative lupus nephritis. Autoimmune Dis. 2017;2017:1872846.
   PubMed Web of Science ®Google Scholar
• Hill GS, Delahousse M, Nochy D, et al. Class IV-S versus class IV-G lupus nephritis: clinical and morphologic differences suggesting different pathogenesis. Kidney Int. 2005;68:2288–2297.
   PubMed Web of Science ®Google Scholar
• Balafa O, Kalaitzidis R, Liapis G, et al. Crescentic glomerulonephritis and membranous nephropathy: a rare coexistence. Int Urol Nephrol. 2015;47:1373–1377.
   PubMed Web of Science ®Google Scholar
• Isono M, Araki H, Haitani T, et al. Diffuse alveolar hemorrhage in lupus nephritis complicated by microscopic polyangiitis. Clin Exp Nephrol. 2011;15:294–298.
   PubMed Web of Science ®Google Scholar
• Wang Y, Huang X, Cai J, et al. Clinicopathologic characteristics and outcomes of lupus nephritis with antineutrophil cytoplasmic antibody: a retrospective study. Medicine (Baltimore). 2016;95:e2580.
   PubMed Web of Science ®Google Scholar
• Sharmeen S, Cassol C, Kato H. ANCA-associated necrotizing glomerulonephritis overlapping with mesangial proliferative lupus nephritis refractory to plasmapheresis, steroid pulse therapy, and a combination of mycophenolate mofetil and rituximab. Case Rep Rheumatol. 2018;2018:3076806.
   PubMedGoogle Scholar
• Abe Y, Shima T, Izumi Y, et al. Successful management of lupus nephritis with high titers of myeloperoxidase anti-neutrophil cytoplasmic antibodies using tacrolimus. Intern Med. 2015;54:2929–2933.
   PubMed Web of Science ®Google Scholar
• Tesar V, Hruskova Z. Limitations of standard immunosuppressive treatment in ANCA-associated vasculitis and lupus nephritis. Nephron Clin Pract. 2014;128:205–215.
   PubMedGoogle Scholar
• Alaiya A, Assad L, Alkhafaji D, et al. Proteomic analysis of Class IV lupus nephritis. Nephrol Dial Transplant. 2015;30:62–70.
   PubMed Web of Science ®Google Scholar
• Hogan JJ, Markowitz GS, Radhakrishnan J. Drug-induced glomerular disease: immune-mediated injury. Clin J Am Soc Nephrol. 2015;10:1300–1310.
   PubMed Web of Science ®Google Scholar
• Mastroianni-Kirsztajn G, Hornig N, Schlumberger W. Autoantibodies in renal diseases – clinical significance and recent developments in serological detection. Front Immunol. 2015;6:221.
   PubMed Web of Science ®Google Scholar
• Turner-Stokes T, Wilson HR, Morreale M, et al. Positive antineutrophil cytoplasmic antibody serology in patients with lupus nephritis is associated with distinct histopathologic features on renal biopsy. Kidney Int. 2017;92:1223–1231.
   PubMed Web of Science ®Google Scholar
• Li Q, Song D, Wang F, et al. Clinicopathological characteristics and outcomes of Chinese patients with scanty immune deposits lupus nephritis: a large cohort study from a single center. ScientificWorldJournal. 2014;2014:212597.
   PubMedGoogle Scholar
• Kim YH, Kim HR, Ham YR, et al. A case of membranous glomerulonephritis with superimposed anti-neutrophil cytoplasmic antibody-associated rapidly progressive crescentic glomerulonephritis. Chonnam Med J. 2015;51:102–105.
   PubMedGoogle Scholar
• Koenig KF, Kalbermatter SA, Menter T, et al. Rapidly progressive lupus nephritis with extremely high levels of antineutrophil cytoplasmic antibodies. Case Rep Nephrol Dial. 2014;4:5–11.
   Google Scholar
• Makiishi T, Shirase T, Yamamoto S, et al. AP-VAS 2012 case report: a case of lupus nephritis with predominant synchronous cellular crescent formation and myeloperoxidase-antineutrophil cytoplasmic antibody seropositivity. CEN Case Rep. 2013;2:134–138.
   PubMedGoogle Scholar
• Jarrot PA, Chiche L, Hervier B, et al. Systemic lupus erythematosus and antineutrophil cytoplasmic antibody-associated vasculitis overlap syndrome in patients with biopsy-proven glomerulonephritis. Medicine. 2016;95:e3748.
   PubMed Web of Science ®Google Scholar
• Bao L, Osawe I, Puri T, et al. C5a promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist. Eur J Immunol. 2005;35:2496–2506.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Colombo BM, Puppo F. Emerging biological drugs: a new therapeutic approach for systemic lupus erythematosus. An update upon efficacy and adverse events. Autoimmun Rev. 2011;11:56–60.
   PubMed Web of Science ®Google Scholar
• Lamprecht P, Kerstein A, Klapa S, et al. Pathogenetic and clinical aspects of anti-neutrophil cytoplasmic autoantibody-associated vasculitides. Front Immunol. 2018;9:680.
   PubMed Web of Science ®Google Scholar
• Huugen D, van Esch A, Xiao H, et al. Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice. Kidney Int. 2007;71:646–654.
   PubMed Web of Science ®Google Scholar
• Xiao H, Dairaghi DJ, Powers JP, Ertl LS, et al. C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol. 2014;25:225–231.
   PubMed Web of Science ®Google Scholar
• Mathern DR, Heeger PS. Molecules great and small: the complement system. Clin J Am Soc Nephrol. 2015;10:1636–1650.
   PubMed Web of Science ®Google Scholar
• McAdoo SP, Bhangal G, Page T, et al. Correlation of disease activity in proliferative glomerulonephritis with glomerular spleen tyrosine kinase expression. Kidney Int. 2015;88:52–60.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhao Z, Hu X. Effect of rituximab on serum levels of anti-C1q and antineutrophil cytoplasmic autoantibodies in refractory severe lupus nephritis. Cell Biochem Biophys. 2015;72:197–201.
   PubMed Web of Science ®Google Scholar
• Ma TK, McAdoo SP, Tam FW. Targeting the tyrosine kinase signalling pathways for treatment of immune-mediated glomerulonephritis: from bench to bedside and beyond. Nephrol Dial Transplant. 2017;32:i129–i38.
   PubMed Web of Science ®Google Scholar
• Krohn S, Nies JF, Kapffer S, et al. IL-17C/IL-17 receptor E signaling in CD4(+) T cells promotes TH17 cell-driven glomerular inflammation. J Am Soc Nephrol. 2018;29:1210–1222.
   PubMed Web of Science ®Google Scholar